Entries by Maui Derm News

Cemiplimab (REGN2810), a fully human anti-PD-1 monoclonal antibody, for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Initial safety and efficacy from expansion cohorts of Phase I study

Cemiplimab (REGN2810), a fully human anti-PD-1 monoclonal antibody, for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Initial safety and efficacy from expansion cohorts of Phase I study Presenters: Papadopoulos KP1,Owonikoko TK2, Johnson ML3, Bra?a I4, Gil-Martin M5, Perez RP6, Moreno V7, Salama AK8, Calvo E9,Yee NS10, Safran H11, González-Martín A12, […]

A real-world study evaluating adequacy of existing systemic treatments for patients with moderate-to-severe atopic dermatitis (AD-QUEST): baseline treatment patterns and unmet needs assessment

A real-world study evaluating adequacy of existing systemic treatments for patients with moderate-to-severe atopic dermatitis (AD-QUEST): baseline treatment patterns and unmet needs assessment Presenters: Wei W1, Ghorayeb W2, Andria ML3, Walker V4, Chao J3, Schnitzer J2, Kennedy M3, Chen Z3; Belland A4, White J4, Silverberg JI5 Affiliations: 1Formerly of Sanofi, Bridgewater, NJ; 2Sanofi, Bridgewater, NJ; […]

An investigator blinded randomized study evaluating hypochlorous acid (HOCl) in the treatment of atopic dermatitis-associated pruritus

An investigator blinded randomized study evaluating hypochlorous acid (HOCl) in the treatment of atopic dermatitis-associated pruritus Presenters: Berman B, Nestor M Affiliation: Center for Clinical and Cosmetic Research and University of Miami Miller School of Medicine, Miami, FL Background/Objective: Hypochlorous acid (HOCl) might potentially reduce pruritus in atopic dermatitis (AD) by its microbicidal qualities, particularly […]

A Phase IIb dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate-to-severe atopic dermatitis (AD)

A Phase IIb dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate-to-severe atopic dermatitis (AD) Presenters: Wollenberg A1, Howell MD2, Guttman-Yassky E3, Silverberg JI4, Birrell C5, Kell C5, Ranade K2, Dawson M5, van der Merwe R5 Affiliations: 1Ludwig Maximillian University, Munich, Germany; 2MedImmune, LLC, MD; 3Mount Sinai School of Medicine, NY; 4Northwestern […]

Clinical efficacy and tolerability of a hydroquinone-free and retinol-free topical brightening serum on females with facial melasma

Clinical efficacy and tolerability of a hydroquinone-free and retinol-free topical brightening serum on females with facial melasma Presenters: Makino ET, Tan P; Mehta RC Affiliation: Research & Development SkinMedica, an Allergan Company, Irvine, CA Background/Objective: Melasma, a progressive form of hyperpigmentation, occurs more often in healthy women than men. The actual etiology is indefinite; however, […]

Understanding the African American facial aesthetic patient

Understanding the African American facial aesthetic patient Presenters: Boyd C1, Alexis A2, Callender V3, Downie J4, Shumate GT5, Gallagher CJ5 Affiliations: 1BOYD, Birmingham, MI; 2Icahn School of Medicine at Mount Sinai, New York, NY; 3Callender Dermatology and Cosmetic Center, Glenn Dale, MD; 4Image Dermatology, Montclair, NJ; 5Allergan plc, Irvine, CA Background/Objective: Aesthetic injectors might perceive […]

Efficacy, safety, and patient-reported outcomes following onabotulinumtoxinA treatment for moderate-to-severe forehead lines: a pooled analysis of two Phase III pivotal trials

Presenters: De Boulle K1, Fagien S2, Mao C3, Shumate GT3, Gallagher CJ3 Affiliations: 1Aalst Dermatology Clinic, Aalst, Belgium; 2Aesthetic Eyelid Plastic Surgery, Boca Raton, FL; 3Allergan plc, Irvine, CA Background/Objective: Two pivotal, Phase III studies were conducted to evaluate the safety and efficacy of onabotulinumtoxinA (onabotA) versus placebo (PBO) for treatment of moderate-to-severe forehead lines […]

Reduction of submental fat continues beyond 28 days after ATX-101 treatment: results from a post-hoc analysis

Reduction of submental fat continues beyond 28 days after ATX-101 treatment: results from a post-hoc analysis Presenters: Dover JS1, Shridharani SM2, Bloom JD3, Somogyi C4, Gallagher CJ4 Affiliations: 1SkinCare Physicians, Chestnut Hill, MA; 2LUXURGERY, New York, NY; 3Main Line Center for Laser Surgery, Ardmore, PA; 4Allergan plc, Irvine, CA Background/Objective: ATX-101 (deoxycholic acid injection) is […]

Subject satisfaction demonstrated for two on-label injection volumes of abobotulinumtoxinA (ABO) when used to treat moderate-to-severe glabellar lines

Subject satisfaction demonstrated for two on-label injection volumes of abobotulinumtoxinA (ABO) when used to treat moderate-to-severe glabellar lines Presenters: Cohen J1, Kaufman J2, Peredo M3, Jonas B4, Nogueira A4, Mashburn J4 Affiliations: 1Director of AboutSkin Dermatology and DermSurgery, Greenwood Village and Lone Tree, CO, Associate Clinical Professor, Department of Dermatology, University of Colorado, CO, and […]

Differential facial aesthetic treatment considerations for skin of color populations: African American, Asian and Hispanic

Differential facial aesthetic treatment considerations for skin of color populations: African American, Asian and Hispanic Presenters: Boyd C1, Chiu A2, Montes JR3, Narurkar V4; Shumate GT5, Gallagher CJ5 Affiliations: 1BOYD, Birmingham, MI; 2The Derm Institute, Hermosa Beach, CA; 3José Raúl Montes Eyes & Facial Rejuvenation, San Juan, PR; 4Bay Area Laser Institute, San Francisco, CA; […]